Avere, NextCure's Merger Partner, Unveils Private Placement and Updated Phase 1 Data for Once-Weekly Oral Psoriasis Drug
NXTC has more than doubled off its 52-week low of $1.55 on light trading volume (0.2× avg).
Summary
Avere, NextCure's merger partner, disclosed a private placement to fund AVR-001 through Phase 2b readouts and presented updated Phase 1 data showing a 57% PASI 75 response at week 8 for the once-weekly oral psoriasis drug.
Key Events · M&A and Partnerships · NXTC
-
Private Placement to Fund Pipeline
Avere is conducting a private placement to raise capital, with pre-closing financings expected to fund the combined company through Phase 2b psoriasis and ulcerative colitis readouts and initiation of Phase 3 trials.
-
Updated Phase 1 Data for AVR-001
The corporate presentation shows AVR-001 achieved a 57% PASI 75 response rate at week 8 in a Phase 1 MAD study, with a safety profile comparable to placebo and no dose-limiting toxicity in chronic toxicology studies.
-
Financing Milestones
Avere closed on $251 million of convertible notes and completed chronic toxicology studies in non-human primates and rats, supporting advancement into later-stage trials.
-
Anticipated Clinical Milestones
Phase 2b psoriasis initiation is expected in 2027, with readout in the first half of 2028; Phase 2b ulcerative colitis initiation also in 2027; Phase 3 psoriasis initiation in 2028.
Analysis · NXTC · Life Sciences
Avere Therapeutics, which is merging with NextCure in a deal that leaves legacy NextCure holders with only ~1.89% of the combined company, is now raising capital through a private placement to fund its lead asset AVR-001 through key clinical readouts. The updated corporate presentation shows encouraging Phase 1 data for the once-weekly oral IL-23 receptor antagonist, with PASI 75 response rates of 57% at week 8 and a safety profile supporting advancement. The financing is expected to fund the company through Phase 2b psoriasis and ulcerative colitis readouts and initiation of Phase 3 trials, de-risking the combined entity's pipeline. For NextCure shareholders, the private placement and clinical progress directly impact the value of the post-merger company they will own a tiny fraction of.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $4.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.